Cardiol Therapeutics Statistics
Total Valuation
CRDL has a market cap or net worth of $88.82 million. The enterprise value is $66.87 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRDL has 82.61 million shares outstanding. The number of shares has increased by 11.02% in one year.
| Current Share Class | 82.61M |
| Shares Outstanding | 82.61M |
| Shares Change (YoY) | +11.02% |
| Shares Change (QoQ) | +15.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 78.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.17 |
| P/TBV Ratio | 5.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.52 |
| Quick Ratio | 4.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -138.47% and return on invested capital (ROIC) is -94.44%.
| Return on Equity (ROE) | -138.47% |
| Return on Assets (ROA) | -73.43% |
| Return on Invested Capital (ROIC) | -94.44% |
| Return on Capital Employed (ROCE) | -162.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.42M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.20% in the last 52 weeks. The beta is 0.67, so CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -39.20% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.60 |
| Relative Strength Index (RSI) | 55.77 |
| Average Volume (20 Days) | 198,066 |
Short Selling Information
The latest short interest is 1.85 million, so 2.23% of the outstanding shares have been sold short.
| Short Interest | 1.85M |
| Short Previous Month | 1.76M |
| Short % of Shares Out | 2.23% |
| Short % of Float | 2.35% |
| Short Ratio (days to cover) | 7.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.99M |
| Pretax Income | -21.99M |
| Net Income | -25.49M |
| EBITDA | -27.88M |
| EBIT | -27.99M |
| Earnings Per Share (EPS) | -$0.36 |
Full Income StatementBalance Sheet
The company has $21.25 million in cash and $110,180 in debt, giving a net cash position of $21.14 million or $0.26 per share.
| Cash & Cash Equivalents | 21.25M |
| Total Debt | 110,180 |
| Net Cash | 21.14M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 17.19M |
| Book Value Per Share | 0.21 |
| Working Capital | 17.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.42 million and capital expenditures -$14,797, giving a free cash flow of -$18.06 million.
| Operating Cash Flow | -17.42M |
| Capital Expenditures | -14,797 |
| Free Cash Flow | -18.06M |
| FCF Per Share | -$0.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |